Literature DB >> 24710366

Long-acting HIV drugs advanced to overcome adherence challenge.

Elie Dolgin.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24710366     DOI： 10.1038/nm0414-323

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Authors:  Prasanta K Dash; Howard E Gendelman; Upal Roy; Shantanu Balkundi; Yazen Alnouti; Rodney L Mosley; Harris A Gelbard; Joellyn McMillan; Santhi Gorantla; Larisa Y Poluektova
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

2.  Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.

Authors:  Jennifer Williams; Harlan R Sayles; Jane L Meza; Patrick Sayre; Uriel Sandkovsky; Howard E Gendelman; Charles Flexner; Susan Swindells
Journal:  Nanomedicine (Lond)       Date:  2013-04-23       Impact factor: 5.307

3.  Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Authors:  Nagsen Gautam; Upal Roy; Shantanu Balkundi; Pavan Puligujja; Dongwei Guo; Nathan Smith; Xin-Ming Liu; Benjamin Lamberty; Brenda Morsey; Howard S Fox; Joellyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

4.  Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Authors:  Chasity D Andrews; William R Spreen; Hiroshi Mohri; Lee Moss; Susan Ford; Agegnehu Gettie; Kasi Russell-Lodrigue; Rudolf P Bohm; Cecilia Cheng-Mayer; Zhi Hong; Martin Markowitz; David D Ho
Journal:  Science       Date:  2014-03-04       Impact factor: 47.728
  4 in total
  29 in total

1.  Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.

Authors:  Mahta Samizadeh; Xiaoping Zhang; Simi Gunaseelan; Antoinette G Nelson; Matthew S Palombo; Daniel R Myers; Yashveer Singh; Usha Ganapathi; Zoltan Szekely; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

2.  Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins.

Authors:  Alice Sosic; Irene Saccone; Caterina Carraro; Thomas Kenderdine; Elia Gamba; Giuseppe Caliendo; Angela Corvino; Paola Di Vaio; Ferdinando Fiorino; Elisa Magli; Elisa Perissutti; Vincenzo Santagada; Beatrice Severino; Valentina Spada; Dan Fabris; Francesco Frecentese; Barbara Gatto
Journal:  Bioconjug Chem       Date:  2018-06-12       Impact factor: 4.774

3.  Generation of a long-acting fusion inhibitor against HIV-1.

Authors:  Ye Guo; Pan-Pan Zhou; Sen-Yan Zhang; Xiao-Wen Fan; Yu-Wei Dou; Xuan-Ling Shi
Journal:  Medchemcomm       Date:  2018-06-06       Impact factor: 3.597

4.  Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.

Authors:  Antons Sizovs; Fernanda P Pons-Faudoa; Gulsah Malgir; Kathryn A Shelton; Lane R Bushman; Corrine Ying Xuan Chua; Peter L Anderson; Pramod N Nehete; K Jagannadha Sastry; Alessandro Grattoni
Journal:  Int J Pharm       Date:  2020-07-11       Impact factor: 5.875

Review 5.  Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.

Authors:  David N Burns; Cynthia Grossman; Jim Turpin; Vanessa Elharrar; Fulvia Veronese
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

6.  Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.

Authors:  John M Cortez; Rafaela Quintero; John A Moss; Martin Beliveau; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 7.  Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups.

Authors:  Onyema Ogbuagu; R Douglas Bruce
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

8.  Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.

Authors:  Manjula Gunawardana; Mariana Remedios-Chan; Christine S Miller; Rob Fanter; Flora Yang; Mark A Marzinke; Craig W Hendrix; Martin Beliveau; John A Moss; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

9.  Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.

Authors:  George J Greene; Greg Swann; Angela J Fought; Alex Carballo-Diéguez; Thomas J Hope; Patrick F Kiser; Brian Mustanski; Richard T D'Aquila
Journal:  AIDS Behav       Date:  2017-05

10.  Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.

Authors:  Pavan Puligujja; Shantanu S Balkundi; Lindsey M Kendrick; Hannah M Baldridge; James R Hilaire; Aditya N Bade; Prasanta K Dash; Gang Zhang; Larisa Y Poluektova; Santhi Gorantla; Xin-Ming Liu; Tianlei Ying; Yang Feng; Yanping Wang; Dimiter S Dimitrov; JoEllyn M McMillan; Howard E Gendelman
Journal:  Biomaterials       Date:  2014-12-09       Impact factor: 12.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.